1. Alemtuzumab CARE-MS I 5-year follow-up: Durable efficacy in the absence of continuous MS therapy. (12th September 2017) Authors: Havrdova, Eva; Arnold, Douglas L.; Cohen, Jeffrey A.; Hartung, Hans-Peter; Fox, Edward J.; Giovannoni, Gavin; Schippling, Sven; Selmaj, Krzysztof W.; Traboulsee, Anthony; Compston, D. Alastair S.; Margolin, David H.; Thangavelu, Karthinathan; Rodriguez, Claudio E.; Jody, Darlene; Hogan, Richard J... Journal: Neurology Issue: Volume 89:Number 11(2017) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Alemtuzumab CARE-MS II 5-year follow-up: Efficacy and safety findings. (12th September 2017) Authors: Coles, Alasdair J.; Cohen, Jeffrey A.; Fox, Edward J.; Giovannoni, Gavin; Hartung, Hans-Peter; Havrdova, Eva; Schippling, Sven; Selmaj, Krzysztof W.; Traboulsee, Anthony; Compston, D. Alastair S.; Margolin, David H.; Thangavelu, Karthinathan; Chirieac, Madalina C.; Jody, Darlene; Xenopoulos, Pano... Journal: Neurology Issue: Volume 89:Number 11(2017) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗